An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy

Yunjiang Zhou; Yaxin Chen; Yingying Tan; Rong Hu; Miao-Miao Niu

doi:10.1002/adhm.202002197

An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy

Adv Healthc Mater. 2021 May;10(9):e2002197. doi: 10.1002/adhm.202002197. Epub 2021 Mar 9.

Authors

Yunjiang Zhou¹, Yaxin Chen¹, Yingying Tan¹, Rong Hu¹, Miao-Miao Niu¹

Affiliation

¹ Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.

PMID: 33690977
DOI: 10.1002/adhm.202002197

Abstract

Supramolecular nanomedicines based on self-assembly of D-peptides have been of great interest as potential candidates for cancer therapy. Neuropilin-1 (NRP1) and mouse double minute 2 (MDM2) have been considered as the anticancer targets because of their overexpression in cancers. However, NRP1/MDM2-targeted D-peptide supramolecular nanomedicines remain unreported. Here, a potent anticancer D-peptide supramolecular nanomedicine targeting NRP1 and MDM2, termed as NMTP-5, is identified by using structure-based virtual screening techniques. NMTP-5 exhibits good biostability and strong cellular uptake performance. Moreover, NMTP-5 displays strong anticancer activity to SK-Hep-1 cells in vitro and in vivo, with no apparent host toxicity. This work demonstrates that NMTP-5 can be used as a potential chemotherapeutic agent for the treatment of liver cancer.

Keywords: D-peptides; MDM2; NRP1; liver cancer therapy; supramolecular nanomedicine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Drug Delivery Systems
Liver Neoplasms* / drug therapy
Mice
Nanomedicine*
Neuropilin-1
Peptides

Substances

Peptides
Neuropilin-1